This study evaluates the effectiveness of topical NAVS naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Half of participants with OLP and RAS will receive topical NAVS naphthalan in adhesive paste, while the other half will receive 0.05%-betamethasone dipropionate in adhesive paste. Our hypothesis is that NAVS could be efficient in the treatment of OLP and RAS, with effects comparable to that of topical steroids.

开始日期2010-12-01

申办/合作机构

University of Zagreb

[+1]

100 项与 NAVS naphthalan 相关的临床结果

登录后查看更多信息

100 项与 NAVS naphthalan 相关的转化医学

登录后查看更多信息

100 项与 NAVS naphthalan 相关的专利（医药）

登录后查看更多信息

项与 NAVS naphthalan 相关的文献（医药）

2024-03-01·Cell Biochemistry and Function

Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside

Review

作者: Kaur, Irwanjot ; Mustafa, Yasser Fakri ; Hjazi, Ahmed ; Redhee, Ahmed Huseen ; Alwaily, Enas R. ; Al‐Hawary, Sulieman Ibraheem Shelash ; Jasim, Saade Abdalkareem ; Kumar, Abhinav ; Al‐Ani, Ahmed Muzahem ; Oghenemaro, Enwa Felix

AbstractOvarian cancer continues to be a difficult medical issue that affects millions of individuals worldwide. Important platforms for cancer immunotherapy include checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, cancer vaccines, and other cell‐based treatments. To avoid numerous infectious illnesses, conventional vaccinations based on synthetic peptides, recombinant subunit vaccines, and live attenuated and inactivated pathogens are frequently utilized. Vaccine manufacturing processes, however, are not entirely safe and carry a significant danger of contaminating living microorganisms. As a result, the creation of substitute vaccinations is required for both viral and noninfectious illnesses, including cancer. Recently, there has been testing of nucleic acid vaccines, or NAVs, as a cancer therapeutic. Tumor antigens (TAs) are genetically encoded by DNA and mRNA vaccines, which the host uses to trigger immune responses against ovarian cancer cells that exhibit the TAs. Despite being straightforward, safe, and easy to produce, NAVs are not currently thought to be an ideal replacement for peptide vaccines. Some obstacles to this strategy include selecting the appropriate therapeutic agents (TAs), inadequate immunogenicity, and the immunosuppressive characteristic of ovarian cancer. We focus on strategies that have been employed to increase NAVs' effectiveness in the fight against ovarian cancer in this review.

2022-07-01·Neuropharmacology2区 · 医学

The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state

2区 · 医学

Article

作者: Kong, Xiangjin ; Wu, Xiangyue ; Khanna, Rajesh ; Luo, Guoqing ; Perez-Miller, Samantha ; Liao, Qingyi ; Liu, Zhonghua ; Li, Yinping ; Tang, Cheng ; Liang, Songping

Noxious pain signals are transduced in the peripheral nervous system as action potentials, which rely on the activities of voltage-gated sodium channels (NaVs). Blocking NaVs is thus a valuable strategy for pain treatment. Here, we report the characterization of a novel NaVs antagonist, 2-(2-(diethylamino)ethyl)indeno[1,2,3-de]phthalazin-3(2H)-one (C65780), and investigation of its action mechanisms. C65780 inhibited the resting NaV1.7, NaV1.8, and NaV1.9 channels with IC₅₀s of 11.3 ± 0.4 μM, 2.7 ± 0.3 μM and 19.2 ± 2.3 μM, respectively. Mechanistic analysis revealed that C65780 quickly bound to its high-affinity receptor site in NaV1.7 as formed by the fast inactivation process and stabilized the channels in a slowly recovering state, for which it facilitated NaV1.7 channels' inactivation by shifting their inactivation-voltage relationship in the hyperpolarizing direction, increasing the plateau proportion of inactivated channels, and blunting their time-dependent recovery. The slow inactivation of NaV1.7, however, is not involved in the action of C65780. In DRG neurons, C65780 also inhibited activity of NaVs, thus dampening neuronal excitability. These effects parlayed into a broad efficacy of orally administrated C65780 in various models of pain, with an efficacy comparable to the antidepressant/neuropathic pain drug Amitriptyline. Excitingly, C65780 demonstrated weaker inactivated state inhibition of related NaV1.4 and NaV1.5 channels compared to amitriptyline, and no toxicity or inhibition of locomotion in a forced-swimming test was observed in mice at pain-relieving doses. These results demonstrate that C65780 acts by trapping NaVs in the inactivated and slowly-recovering state to produce pain relief and may represent an excellent starting compound for developing analgesics.

2020-04-01·Drug Research

The Efficacy of the Comprehensive Use of Naphthalan and Non-Selective Chromotherapy in the Treatment of Patients with Gonarthrosis

Article

作者: Abramovich, Stanislav G. ; Koneva, Elizaveta S. ; Drobyshev, Victor A. ; Makhova, Anna A.

AbstractIn the last decade, a new direction of phototherapy – the non-selective chromotherapy (NSC) with Bioptron – has become widespread in clinical physiotherapy. The aim of the study was the scientific justification of the comprehensive treatment of patients with osteoarthritis of knee joints, including the combined use of refined naphthalan applications and irradiation with incoherent polarized Bioptron light. The article presents the results of the study which investigated the efficacy of the comprehensive treatment of osteoarthritis of knee joints in patients using the combined exposure to naphthalan applications with irradiation using the non-selective Bioptron chromotherapy in the sanatorium. 64 patients aged 40–69 years with stage 1–3 knee osteoarthritis were examined and treated. It was shown that the combined use of naphthalan and non-selective chromotherapy in patients with gonarthrosis reduces pain, improves the functional state of the affected knee joints and improves the quality of life of patients in the absence of adverse effects. A comparative analysis of the study results showed that the efficacy of the combined use of naphthalan and non-selective chromotherapy is superior to the isolated effect of naphthalan.

100 项与 NAVS naphthalan 相关的药物交易

登录后查看更多信息